- Home
- Decoding the Future of Heart Failure — Emerging Strategies in HF with EF ≥40%: Key Takeaways from 2024
Decoding the Future of Heart Failure — Emerging Strategies in HF with EF ≥40%: Key Takeaways from 2024
- Heart Failure
- HFpEF
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
This educational programme , recorded at the American Heart Association 2024 conference in Chicago, provides an in-depth exploration of cardiometabolic disease in patients with heart failure with mid-range or preserved ejection fraction (HFmrEF and HFpEF).
Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, Boston, US), Dr Orly Vardeny (University of Minnesota Medical School, Minneapolis, US) and Prof Pardeep Jhund (University of Glasgow, Glasgow, UK) leverage the latest research and data presented at the conference to deliver comprehensive insights into the clinical management of these conditions. Participants will gain a thorough understanding of cutting-edge findings and their implications for practice, learning how to apply evidence-based strategies to improve outcomes for patients with heart failure and associated metabolic disorders.
With a focus on advanced, targeted interventions, the programme equips clinicians with the knowledge and tools necessary to address the unique challenges posed by this complex patient population. By integrating the most current evidence and practical approaches, this course empowers healthcare providers to deliver enhanced, personalised care for improved patient outcomes.
This education was developed by Radcliffe Medical Communications (Eire) Ltd.
Support Statement
This programme is supported by an unrestricted educational grant from Bayer.
This educational programme was developed by Radcliffe Medical Communications (Eire) Ltd.
Disclosure
In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session, ‘Decoding the Future of Heart Failure — Emerging Strategies in HF with EF ≥40%: Key Takeaways from 2024’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Instruction to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Target Audience
Target Audience:
- Cardiologists
- Internists
- Heart Failure Specialists
- General Practitioners
- Nurse Practitioners
- Cardiovascular Nurses
- Allied Healthcare Professionals
Learning Objectives
Upon completion of this activity, participants will be able to:
- Summarise the long-term burden and current unmet needs for patients with HF and EF ≥40%
- Recall data on new therapies being evaluated in the HFmr/pEF population, including data from the AHA 2024 annual congress
- Describe how non-steroidal MRAs differ in their mechanism of action and elicit their benefits in HF
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Part 1 | Unmet Needs in Individuals With Hf and Ef ≥40% | 10m 59s | Muthiah Vaduganathan |
| Part 2 | Are Novel MRAs the Answer? | 12m 4s | Pardeep Jhund |
| Part 3 | New Approaches in HF With EF ≥40% | 13m 20s | Orly Vardeny |
| Part 4 | Modernising Our Practice in the HFmr/pEF Population and Q&A | 10m 37s | Muthiah Vaduganathan Orly Vardeny Pardeep Jhund |
Modernising Our Practice in the HFmr/pEF Population and Q&A
Duration: 10m 37s
Speakers: Muthiah Vaduganathan Orly Vardeny Pardeep Jhund
Related Courses
- 1.00
Published:
Learning objectives
- Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
- Select appropriate patients for advanced medical therapy
- Recall recent trial data for novel therapeutic approaches
- Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
- 1.25
Published:
Learning objectives
- To identify high-risk patient features indicative of worsening Heart Failure (HF)
- Name validated tools for serial prognostic assessment and risk stratification
- Adopt the use of appropriate assessment tools during patient follow-up
- Recall rates of recurrent HF events and their associated healthcare costs in worsening HF patients
- Recall the clinical benefit of emerging treatments targeted to treating worsening HF
- Initiate available treatment for the tailored management of worsening HF
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
- Not accredited
Published:
Learning objectives
- Recall guideline recommendations for the use of NT-proBNP in heart failure
- Describe current practices in heart failure diagnosis and the impact on treatment outcomes
- Develop an optimised approach to the timely diagnosis and management of heart failure
- 2.00
Published:
Learning objectives
- Recall clinical evidence and guidelines for the management of CKD patients without diabetes
- Describe current gaps and barriers in evidence-based management for CKD without diabetes
- Apply evidence based-management strategies to a case study
- Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
- Not accredited
Published:
Learning objectives
- Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
- Apply latest guideline recommendations to patient cases
- Describe barriers preventing early initiation of GDMT
- Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
- Identify the importance of the nurse/cross-functional team
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists